XML 25 R5.htm IDEA: XBRL DOCUMENT v2.3.0.15
Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)
9 Months Ended
Sep. 30, 2011
Sep. 30, 2010
Cash flows from operating activities:  
Net loss$ (14,116,780)$ (16,286,678)
Adjustments to reconcile net loss to net cash used in operating activities:  
Depreciation and amortization917,1471,169,054
Stock-based compensation2,636,4452,987,883
Gain on sale of marketable securities(83,750) 
Gain from settlement agreement, net (226,580)
Loss on disposal of fixed assets32,1451,854
Write-down of fixed assets 62,807
Write-down of intangible assets 35,684
Change in fair value of warrant liability(6,500,377)(5,184,304)
Changes in operating assets and liabilities:  
Other receivables252558,709
Trade receivables(281,709)54,309
Prepaid and other current assets465,514(209,259)
Other assets, non-current18,83042,482
Accounts payable and accrued expenses(142,120)(1,706,687)
Accrued wind-down expenses(820,708)(762,474)
Deferred revenue(4,541)(61,289)
Deferred rent1,034,088(130,768)
Net cash used in operating activities(16,845,564)(19,655,257)
Cash flows from investing activities:  
Purchase of marketable securities(10,223,957) 
Proceeds from the sale and maturity of marketable securities5,134,206 
Purchases of property, plant and equipment(330,740)(766,907)
Proceeds from sale of property, plant and equipment42,427 
Net cash used in investing activities(5,378,064)(766,907)
Cash flows from financing activities:  
Proceeds from issuance of common stock, net of issuance costs10,426,1217,015,322
Proceeds from the exercise of stock options2,38618,936
Payments related to net share issuance of stock based awards(396,201)(483,406)
Repayment of capital lease obligations(50,246)(52,069)
Repayment of bonds payable(130,000)(118,750)
Net cash provided by financing activities9,852,0606,380,033
Decrease in cash and cash equivalents(12,371,565)(14,042,131)
Effects of foreign exchange rate changes on cash(42,182)(21,272)
Cash and cash equivalents, beginning of period19,707,82138,617,977
Cash and cash equivalents, end of period7,294,07424,554,574
Supplemental disclosure of cash flow information:  
Interest paid56,58572,775
Supplemental schedule of non-cash investing and financing activities:  
Stock retired from settlement agreement* $ 241,150[1]
[1] On April 1, 2009, we acquired the operations of Stem Cell Sciences Plc (SCS), which changed its name to Asset Realisation Company Limited. Pursuant to the acquisition agreement, 53,000 shares were placed into an escrow for a twelve month period to satisfy any indemnification obligations owed to us by SCS. On August 19, 2010, we entered into a settlement agreement with SCS in which the parties agreed to the release of half the escrowed shares to SCS and half to us in full satisfaction of our claims for indemnification, and both parties waived all other claims, known and unknown, against the other. The 26,500 shares returned to us are being treated as retired and no longer outstanding. We have recorded approximately $227,000 as other income, which was the value of these shares based on the closing price of $9.10 per share on August 19, 2010, and net of amounts already accrued for potential claims against the escrowed shares.